Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 4 (April)

1. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.
   Cancer Res, 68(7): 2479-88. [Abstract] [Full-text]
2. Detection of early prostate cancer using a hepsin-targeted imaging agent.
   Cancer Res, 68(7): 2286-91. [Abstract] [Full-text]
3. Down-regulation of mammalian sterile 20-like kinase 1 by heat shock protein 70 mediates cisplatin resistance in prostate cancer cells.
   Cancer Res, 68(7): 2266-74. [Abstract] [Full-text]
4. Lkb1 deficiency causes prostate neoplasia in the mouse.
   Cancer Res, 68(7): 2223-32. [Abstract] [Full-text]
5. Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer.
   Cancer Res, 68(7): 2132-44. [Abstract] [Full-text]
6. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
   Cancer Res, 68(7): 2112-21. [Abstract] [Full-text]
7. Distinct nuclear and cytoplasmic functions of androgen receptor cofactor p44 and association with androgen-independent prostate cancer.
   Proc Natl Acad Sci U S A, 105(13): 5236-41. [Abstract] [Full-text]
8. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells.
   Carcinogenesis, 29(4): 713-21. [Abstract] [Full-text]
9. Induction of multinucleated cells and apoptosis in the PC-3 prostate cancer cell line by low concentrations of polyethylene glycol 1000.
   Cancer Sci, 99(5): 1055-62. [Abstract] [Full-text]
10. Bone marrow stromal cells enhance prostate cancer cell invasion through type I collagen in an MMP-12 dependent manner.
    Int J Cancer, 122(11): 2482-90. [Abstract] [Full-text]
11. Saturated fat intake predicts biochemical failure after prostatectomy.
    Int J Cancer, 122(11): 2581-5. [Abstract] [Full-text]
12. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer.
    Int J Cancer, 122(11): 2511-6. [Abstract] [Full-text]
13. Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.
    Oncogene, 27(15): 2243-8. [Abstract] [Full-text]
14. Experimental and systems biology studies of the molecular basis for the radioresistance of prostate carcinoma cells.
    Ann Biomed Eng, 36(5): 831-8. [Abstract] [Full-text]
15. Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
    Am J Clin Oncol, 31(2): 188-94. [Abstract] [Full-text]
16. Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
    J Clin Oncol, 26(11): 1824-9. [Abstract] [Full-text]
17. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy.
    Immunity, 28(4): 571-80. [Abstract] [Full-text]
18. Is robotically assisted laparoscopic radical prostatectomy less invasive than retropubic radical prostatectomy? Results from a prospective, unrandomized, comparative study.
    BJU Int, 101(9): 1145-9. [Abstract] [Full-text]
19. Effect of a large prostate gland on open and robotically assisted laparoscopic radical prostatectomy.
    BJU Int, 101(9): 1140-4. [Abstract] [Full-text]
20. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
    BJU Int, 101(9): 1084-9. [Abstract] [Full-text]
21. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    BJU Int, 101(9): 1096-100. [Abstract] [Full-text]
22. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
    BJU Int, 101(9): 1077-83. [Abstract] [Full-text]
23. Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.
    BJU Int, 101(9): 1071-5. [Abstract] [Full-text]
24. A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.
    BJU Int, 101(9): 1090-5. [Abstract] [Full-text]
25. Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer.
    J Urol, 179(5): 2020-4. [Abstract] [Full-text]
26. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance.
    J Urol, 179(5): 1804-9; discussion 1809-10. [Abstract] [Full-text]
27. Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005.
    J Urol, 179(5): 1811-7; discussion 1817. [Abstract] [Full-text]
28. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    J Urol, 179(5): 1830-7; discussion 1837. [Abstract] [Full-text]
29. The impact of prostate size on urinary quality of life indexes following laparoscopic radical prostatectomy.
    J Urol, 179(5): 1818-22. [Abstract] [Full-text]
30. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
    J Urol, 179(5): 1762-7; discussion 1767. [Abstract] [Full-text]
31. Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
    J Urol, 179(5): 1768-73; discussion 1773-4. [Abstract] [Full-text]
32. The arachidonic acid pathway and its role in prostate cancer development and progression.
    J Urol, 179(5): 1668-75. [Abstract] [Full-text]
33. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE.
    J Urol, 179(5): 1797-803; discussion 1803. [Abstract] [Full-text]
34. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy.
    J Urol, 179(5): 1780-4; discussion 1784. [Abstract] [Full-text]
35. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database.
    J Urol, 179(5): 1785-9; discussion 1789-90. [Abstract] [Full-text]
36. Tertiary Gleason pattern 5 in Gleason 7 prostate cancer predicts pathological stage and biochemical recurrence.
    J Urol, 179(5): 1775-9. [Abstract] [Full-text]
37. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
    J Urol, 179(5): 1751-5; discussion 1755. [Abstract] [Full-text]
38. Risk stratification for biochemical recurrence in men with positive surgical margins or extracapsular disease after radical prostatectomy: results from the SEARCH database.
    J Urol, 179(5): 1791-6; discussion 1796. [Abstract] [Full-text]
39. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
    J Urol, 179(5): 1756-61; discussion 1761. [Abstract] [Full-text]
40. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men.
    J Urol, 179(5): 1741-4; discussion 1744-5. [Abstract] [Full-text]
41. Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?
    J Urol, 179(5): 1736-40. [Abstract] [Full-text]
42. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
    J Urol, 179(5): 1746-50; discussion 1750. [Abstract] [Full-text]
43. Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice.
    BMC Cancer, 8: 81. [Abstract] [Full-text]
44. Is seeing a specialist nurse associated with positive experiences of care? The role and value of specialist nurses in prostate cancer care.
    BMC Health Serv Res, 8: 65. [Abstract] [Full-text]
45. A haplotype at chromosome Xq27.2 confers susceptibility to prostate cancer.
    Hum Genet, 123(4): 379-86. [Abstract] [Full-text]
46. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Am J Epidemiol, 167(8): 925-34. [Abstract] [Full-text]
47. Curtain dissection of the lateral prostatic fascia and potency after laparoscopic radical prostatectomy: a veil of mystery.
    BJU Int, 101(10): 1285-8. [Abstract] [Full-text]
48. Is the biopsy Gleason score important in predicting outcomes for patients after radical prostatectomy once the pathological Gleason score is known?
    BJU Int, 101(10): 1232-6. [Abstract] [Full-text]
49. High-intensity focused ultrasound in prostate cancer; a systematic literature review of the French Association of Urology.
    BJU Int, 101(10): 1205-13. [Abstract] [Full-text]
50. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.
    BJU Int, 101(10): 1302-9. [Abstract] [Full-text]
51. Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function.
    BJU Int, 101(10): 1217-22. [Abstract] [Full-text]
52. Leptin and adiponectin interact in the regulation of prostate cancer cell growth via modulation of p53 and bcl-2 expression.
    BJU Int, 101(10): 1317-22. [Abstract] [Full-text]
53. Cryoablative response of prostate cancer cells is influenced by androgen receptor expression.
    BJU Int, 101(10): 1310-6. [Abstract] [Full-text]
54. Dietary modification in patients with prostate cancer on active surveillance: a randomized, multicentre feasibility study.
    BJU Int, 101(10): 1227-31. [Abstract] [Full-text]
55. Over-diagnosis and under-diagnosis of screen- vs non-screen-detected prostate cancers with in men with prostate-specific antigen levels of 2.0-10.0 ng/mL.
    BJU Int, 101(10): 1223-6. [Abstract] [Full-text]
56. Colorectal complications of external beam radiation versus brachytherapy for prostate cancer.
    Am J Surg, 195(5): 616-20; discussion 620. [Abstract] [Full-text]
57. How much of the data published in observational studies of the association between diet and prostate or bladder cancer is usable for meta-analysis?
    Am J Epidemiol, 167(9): 1017-26. [Abstract] [Full-text]
58. Detecting trends in noisy data series: application to biomarker series.
    Am J Epidemiol, 167(9): 1130-9. [Abstract] [Full-text]
59. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Cancer, 112(9): 1941-8. [Abstract] [Full-text]
60. Characterization of PacMetUT1, a recently isolated human prostate cancer cell line.
    Prostate, 68(8): 883-92. [Abstract] [Full-text]
61. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
    Prostate, 68(8): 861-71. [Abstract] [Full-text]
62. Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation.
    Prostate, 68(8): 872-82. [Abstract] [Full-text]
63. RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
    Prostate, 68(8): 820-9. [Abstract] [Full-text]
64. Genetic changes and DNA damage responses in the prostate.
    Prostate, 68(8): 902-18. [Abstract] [Full-text]
65. Elevated levels of HER-2/neu and androgen receptor in clinically localized prostate cancer identifies metastatic potential.
    Prostate, 68(8): 830-8. [Abstract] [Full-text]
66. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells.
    Prostate, 68(8): 849-60. [Abstract] [Full-text]
67. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides.
    Prostate, 68(8): 809-19. [Abstract] [Full-text]
68. Gene amplification and mutation analysis of epidermal growth factor receptor in hormone refractory prostate cancer.
    Prostate, 68(8): 803-8. [Abstract] [Full-text]
69. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
    Prostate, 68(8): 839-48. [Abstract] [Full-text]
70. Overexpression of Bax induces down-regulation of store-operated calcium entry in prostate cancer cells.
    J Cell Physiol, 216(1): 172-9. [Abstract] [Full-text]
71. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
    J Clin Oncol, 26(13): 2147-54. [Abstract] [Full-text]
72. Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells.
    Int J Cancer, 123(1): 41-50. [Abstract] [Full-text]
73. A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor.
    Int J Cancer, 123(1): 195-201. [Abstract] [Full-text]
74. FGF-8 is involved in bone metastasis of prostate cancer.
    Int J Cancer, 123(1): 22-31. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.